Case 3:15-cv-00189-PK Document 21
`
`Filed 03/23/15 Page 1 of 10
`
`Nancy Erfle, OSB #902570
`Email: nerfle@gOrdonrees.cOm
`GORDON & REES LLP
`
`121 SW Morrison Street, Suite 1575
`Portland, OR 97204
`Telephone: 503.222.1075
`Facsimile: 503.616.3600
`
`Jennifer D. Hackett, admitted pro hac vice
`Email: hackettj@dicksteinshapiro.com
`DICKSTEIN SHAPIRO LLP
`
`1825 Eye StreetNW
`Washington, DC 20006
`Telephone: 202.420.4413
`Facsimile: 202.420.2201
`
`Attorneys for Defendants
`
`IN THE UNITED STATES DISTRICT COURT
`
`DISTRICT OF OREGON
`
`PORTLAND DIVISION
`
`PARAGON BIOTECK, INC.,
`
`No. 3: 15-CV-00189-PK
`
`Plaintiff,
`
`‘’5-
`
`ALTAIRE PHARMACEUTICALS, INC. and
`SAWAYA AQUEBOGUE, LLC
`
`Defendants.
`
`DECLARATION OF ASSAD
`SAWAYA IN SUPPORT OF
`ALTAIRE PHARMACEUTICALS,
`INC. AND SAWAYA AQUEBOGUE,
`LLC’S MOTION TO DISMISS OR,
`IN THE ALTERNATIVE, FOR
`TRANSFER OF VENUE
`
`I, Assad Sawaya, pursuant to 28 U.S.C. § 1746, under the penalty of perjury, hereby
`
`declare as follows:
`
`Page 1 — DECLARATION OF ASSAD SAWAYA IN
`SUPPORT OF ALTAIRE PHARMACEUTICALS, INC.
`AND SAWAYA AQUEBOGUE, LLC’S MOTION TO
`DISMISS OR, IN THE ALTERNATIVE, FOR
`TRANSFER OF VENUE
`
`Gordon &; Rees LLP
`121 SW Morrison Street, Suite 1575
`Portland, OR 97204
`Telephone: (503) 222-1075
`Facsimile: (503) 616-3600
`
`PARAGON - EXHIBIT 2001
`
`PARAGON - EXHIBIT 2001
`
`

`
`Case 3:15-cv—00189-PK Document 21
`
`Filed 03/23/15 Page 2 of 10
`
`1.
`
`I am President of Altaire Pharmaceuticals, Inc. (“Altaire”) and General Manager
`
`of Sawaya Aquebogue, LLC (“Saw Aque”).
`
`I make this Declaration based upon my personal
`
`knowledge, inquiries within Altaire, and my review of records maintained in the regular course
`
`of business.
`
`2.
`
`Altaire is a New York corporation with its principal place of business in
`
`Aquebogue, New York, located in Suffolk County. All of Altaire’s employees, shareholders,
`
`officers and directors are located in New York.
`
`3.
`
`Altaire manufactures (compounds, fills and packages) liquid and semi-solid
`
`pharmaceutical (both prescription and over-the-counter) and homeopathic products, including
`
`ophthalmic products. All manufacture takes place in New York and the products are stored in
`
`New York.
`
`4.
`
`Saw Aque is a limited liability company organized in New York, with its
`
`principal office in Aquebogue, New York. All of Saw Aque’s employees, shareholders, officers
`
`and directors are located in New York.
`
`5.
`
`6.
`
`Neither Altaire nor Saw Aque is licensed to do business in Oregon.
`
`Neither Altaire nor Saw Aque has any property in Oregon, nor does either
`
`maintain any facilities in Oregon.
`
`7.
`
`Neither Altaire nor Saw Aque has ever sent any employees to Oregon for any
`
`purpose.
`
`8.
`
`Prior to its relationship with Paragon BioTeck, Inc. ("Paragon"), neither
`
`Altaire nor Saw Aque had any business relationship with anyone in Oregon. Except for the
`
`Page 2 — DECLARATION OF ASSAD SAWAYA IN
`SUPPORT OF ALTAIRE PHARMACEUTICALS, INC.
`AND SAWAYA AQUEBOGUE, LLC’S MOTION TO
`DISMISS OR, IN THE ALTERNATIVE, FOR
`TRANSFER OF VENUE
`
`Gordon 8: Rees LLP
`121 SW Morrison Street, Suite 1575
`Portland, OR 97204
`Telephone: (503) 222-1075
`Facsimile: (503) 616-3600
`
`

`
`Case 3:15-cv—00189-PK Document 21
`
`Filed 03/23/15 Page 3 of 10
`
`relationship with Paragon, neither Altaire nor Saw Aque has any current (or planned]
`
`connection with Oregon.
`
`9.
`
`In 2011, a Paragon employee, Patrick Witham, contacted Altaire in New York
`
`and proposed a business relationship.
`
`10.
`
`On May 30, 2011, Paragon and Altaire entered into an Agreement; Patrick
`
`Witham traveled to New York to negotiate the Agreement. No negotiations regarding the
`
`Agreement took place in Oregon. A true and correct copy of the Agreement is attached
`
`hereto as Exhibit 1.
`
`11.
`
`The Agreement states, among other things: “The parties to this Agreement
`
`agree that jurisdiction and venue of any action brought pursuant to this Agreement, to
`
`enforce the term hereof or otherwise with respect to the relationships between the parties
`
`created or extended pursuant hereto, shall properly lie in the Court(s) of the State of New
`
`York or the Court(s) of the United States having jurisdiction over Suffolk County, New
`
`York." The U.S. District Court for the Eastern District of New York has jurisdiction over
`
`Suffolk County, New York.
`
`12.
`
`The Agreement also states: "The validity, construction and enforcement of,
`
`and the remedies under, this Agreement shall be governed in accordance with the laws of
`
`the State of New York.”
`
`13.
`
`Pursuant to the Agreement, Altaire agreed to provide the Chemistry, Manu-
`
`facturing and Controls ["CMC") sections for an New Drug Application ("NDA") Paragon was
`
`to complete and file with the Food and Drug Administration ("FDA") regarding certain
`
`Page 3 — DECLARATION OF ASSAD SAWAYA IN
`SUPPORT OF ALTAIRE PHARMACEUTICALS, INC.
`AND SAWAYA AQUEBOGUE, LLC’S MOTION TO
`DISMISS OR, IN THE ALTERNATIVE, FOR
`TRANSFER OF VENUE
`
`Gordon 8: Rees LLP
`121 SW Morrison Street, Suite 1575
`Po1t1and,OR 97204
`Telephone: (503) 222-1075
`Facsimile: (503) 616-3600
`
`

`
`Case 3:15-cv—00189-PK Document 21
`
`Filed 03/23/15 Page 4 of 10
`
`ophthalmic products. Altaire also agreed to manufacture and supply the products at issue
`
`in the Agreement. The research, development and completion of the CMC sections took
`
`place in New York, and all manufacturing of the products takes place in New York.
`
`14.
`
`The consultant that Paragon hired to assist with the filing of the NDA
`
`was located outside of Oregon.
`
`15.
`
`Altaire shipped the products purchased pursuant to the Agreement to
`
`BioTeck c/o Woodfield Dist., Boca Raton FL and Valeant Pharmaceuticals, Inc., Lehigh
`
`Valley, PA as directed by Paragon's purchase orders.
`
`16.
`
`Since the time that Paragon approached Altaire, Paragon employees have
`
`visited Altaire’s offices in New York on a number of occasions from 2011 through 2014.
`
`17.
`
`Throughout the life of the Agreement, Paragon has sent payments to Altaire
`
`in New York. Paragon's employees also telephone Altaire’s employees in New York on a
`
`regular basis.
`
`18.
`
`Altaire’s activities in Oregon are limited to sending invoices and certain other
`
`documents from time to time to Paragon's Oregon address, and placing telephone calls to
`
`Paragon.
`
`19.
`
`Paragon markets and distributes its products nationwide, including in New
`
`York.
`
`20.
`
`In 2013, Paragon entered into a commercialization and distribution
`
`agreement with Bausch & Lomb, a New York corporation with its headquarters in New
`
`Iersey. As part of the agreement between Paragon and Bausch & Lomb, Bausch & Lomb has
`
`Page 4 — DECLARATION OF ASSAD SAWAYA IN
`SUPPORT OF ALTAIRE PHARMACEUTICALS, INC.
`AND SAWAYA AQUEBOGUE, LLC’S MOTION TO
`DISMISS OR, IN THE ALTERNATIVE, FOR
`TRANSFER OF VENUE
`
`Gordon 8: Rees LLP
`121 SW Morrison Street, Suite 1575
`Portland, OR 97204
`Telephone: (503) 222-1075
`Facsimile: (503) 616-3600
`
`

`
`Case 3:15—cv—00189-PK Document 21
`
`Filed 03/23/15 Page 5 of 10
`
`made payments to Altaire in New York against Altaire’s invoices issued to Paragon for the
`
`sale of Altaire’s products and as instructed by Paragon.
`
`21.
`
`Saw Aque is not a party to the Agreement between Paragon and Altaire.
`
`Pursuant to the Agreement, Paragon agreed to provide certain consideration to Saw Aque.
`
`This is the only connection Saw Aque has with the Agreement or with Paragon.
`
`22.
`
`No one from Saw Aque has ever attended any shareholder [or other)
`
`meetings of Paragon on behalf of Saw Aque.
`
`I declare under penalty of perjury that the foregoing is true and correct. Executed
`
`this 23rd day of March, 2015 at Aquebogue, New York.
`
`/s/ Assad Sawaya
`Assad Sawaya
`
`Page 5 — DECLARATION OF ASSAD SAWAYA IN
`SUPPORT OF ALTAIRE PHARMACEUTICALS, INC.
`AND SAWAYA AQUEBOGUE, LLC’S MOTION TO
`DISMISS OR, IN THE ALTERNATIVE, FOR
`1104214/22mmv.1TRANSFER OF VENUE
`
`Gordon 8: Rees LLP
`121 SW Morrison Street, Suite 1575
`Portland, OR 97204
`Telephone: (503) 222-1075
`Facsimile: (503) 616-3600
`
`

`
`
`
`Case 3:15—cv—00189-PK Document 21 Filed 03/23/15 Page 6 of 10
`
`AGREEMEN T
`
`by and
`30"’ day of M21)’. 20l 1.
`This ..«'\grcctnent (ltet'ei.nal‘ter the “.»\gt'cetnettt") is made this
`between /\.l;f'l"AlRl':'. PH/\RMACl3UT.lCAI.S. INC. having its principal oilicc at 31 l West l,z;ms:.
`Aqttebogttt‘. New York ll93l
`(itcrcinztlter ".~'\l.,"l‘AlRIEI"') and PARAGON BI(:)'il‘i3,CK, INC.
`liming its principal ollittc at
`(.‘ctttcrpointc l)r.. Suite 400 1..-altc <7s\>m.§p. Oregon 97035 (ltcrcinaftcr
`"l"ARA('3C)N").
`
`\’i’lllERlZ.=\S the parties agree that :\l,.'l‘/\lRlE?. will provide the Chemistry. Mztitutitctttrittg arid
`t7ont'rols
`(ltcreinaltcr
`"(_‘i\lC“)
`sections
`ibr an NBA filing for
`the Products
`(ltercin:-titer
`'PR(f)Dl..iCTS’) as icicntiiied herein,
`that Al.,'l'AlRlE will be the exclusive t1tatttulE1cttt1'cr and
`supplier of such Products. that PARAGON shall submit and obtain NDA approval
`for such
`Prodttcts. and that PAR/~\ClC)N shall exclusively lTl31'kC’t and distribute such l’rodttctse. NOW.
`'l"l~ll?Il{l:Zi~‘(")Rl?L-
`in consiclertttion of the foregoing premises, and the mutual covenants.
`stipulations. terms and conditions herein contained. the parties hereby agree as follows:
`
`'il“lE'.RM
`
`"l"cu (Ill) years. The parties may extend the Icon of this Agrcentcnt upon mutttally acceptable
`conditions. indicated in writing, and accepted in writing by it duly ‘clLtlil()I‘i"/.L“d rt*pt‘ttsctttzt‘tivc of‘
`uric}: part
`
`C(f)N l l‘) l}; RA ' l"l (f)i\i
`
`in c.t:tnsitleration for x\l.'l‘,2\lRl.i providing the C.‘;=‘vl(.“ sections for the l’I‘t)(lLlClS itlcntilictl l”lt‘rt.?.il1.
`l’.=\l{A(_it)E\-‘
`sh:-.1ll irr1rnecliately 'to SAVs-’,-'\Y.v'\
`.~’\QU."\.i3OCiUifl,
`l...l'..,C‘.
`it limited liability company incorporated in the state 01' New York and
`liming its priitcipal office at 3l l West Lane. Aquebogue. NY l l93l.
`
`l5’ R0 DU (."l“_‘$
`
`.'=\l_.'l“./\I R1"-L will ptrwidc tilt‘ CMC sections for the followittg products to support Nl)A filings by
`l"x\ R (fl ON :
`
`ttttclcrstoo l by the parties that l’R()D'UC.T'l"S as defined \\=itl'tin this .ACiR.l£EEl\=lLieN'l‘
`it is tigl‘€c)(l'al’1t‘l.
`t3XClLldCS the following:
`
`
`
`‘ Such protlucts ttrc cxclttclccl from ll1i$ atgrcctttettt and all prox-'i.:»'ions herein.
`
`1
`
`" Exhibit A, Page 1.._m_._-J
`
`

`
`Case 3:15—cv—00189-PK Document 21
`
`Filed 03/23/15 Page 7 of 10
`
`lit the cwtit &l1\'?Tl1ilIl\’t‘ products are HC-CCSSEtI'_V. Alfl"‘.»’tll{E will provide the (‘MC SCCll0llS for the
`ti>llt:wviiig products to Sttppfirl ND.»'\ filings by l’AR../\(3(‘)N:
`
`RES]’(T)NSlBllI.,lTll?iS OF PARAGON
`
`l’A.RACi(')i\3 shall be responsible for preparing and submitting the NDA applicatititis in support
`tivt‘ the Pl‘{C)l)l ICTS.
`
`li’;\R./-\(}()N shall bCt‘l.t' all expenses and costs of preparing and submitting the .\‘DA applications.
`ittcluding any additional. supplemental or corrective submissions required by the Food and [)1'ttf__1
`Adl"nlI'llS1TI'8Il()n.
`
`Upon obtaining the NDA approv-a.ls. PARAGON shall exclusively market and distribute such
`Products.
`
`Px\Rt..-:\G(;)‘:\" shall use. zillocutc mid./or distribute profits in a manner crmsistcnt with its llCl1lCl&ll'}
`dttties l0 .‘5l‘t8.I‘CllOlClGl’S. and in accorclztnce with applicable law.
`
`R lt.‘;‘fS_il;’..£ i)..?t§.53_l B I Ll ll liii,Q.l;i-.e:%.ltJLfi.l._._lil
`
`:\l..'l‘.r\ll‘{lfZ will pl‘Ct\’l(lC and hear the costs for the C‘ltcinist‘ry, Mzmttfacturing ttnd Controls
`tlicrcin2't'i.’t.ci'
`'(fM(I‘) scctitms in support of an ?\lII)/\
`filing for
`the Prctducts (ltcrcinal'tcr
`‘l-’R(.)Dl...l(L"l‘S')
`indcntiticd herein, including any amendments or corrccti\-'e CMC subini.ssic>ns
`rcqttircd by the Ftiod and l)rug Administration.
`
`.-'\l...'I“AlRl3 will be the é3XCl1!S.l\’C manufacturer and supplier of such Products upon l’ARAG()l\l
`obtaining the NDA approvals.
`
`£;;.(.2.-Sl_§.LJ_l;“_£_i.(..?.§_3._l..Z$,
`
`"l'licreal‘tet'.
`(it) The amt til‘ grinds pa)-’2iblC to Al.'l'".~\lRl?.‘ Aqucl)t>gtte,
`..~\l,'I‘All'{liT tiiay t"L‘£1SOI‘l£1bl)" adjttst the Cost til‘ Goods annually to reflect
`increases in costs of
`materials. components. sterilimtion of materials/contpotieitts.
`labor. overhead. maintenance.
`rczgulatory cotnplittnce. w:t~3tc disposal and other incidents that may impact on COGS.
`Such
`;itmuz~il increases shall not exceed an increase nfjahove the prior yeat"s cost of goods.
`
`lb‘) l’ayinL=*ttt' Tcmts: Net 60 days from receipt of invoice.
`
`(J I-J‘.,t?‘$ l V l’li")"
`
`«'\l.'l'.e-\Il{l:i vgrecs tn inat1t1fact.tii'e and suppl_\'
`:-1pprm=ttls.
`lffpon obtaining the :\’'l.);\
`(Ll)
`l’l%(i)Dl7(‘T'l‘S tn l’.»‘\RA(..iON an an cxclttsivc basis during the term oftlte A(fil“{lZl;-I;’\*ll;iN”l‘.
`
`the
`
`lv
`
`1*
`
`.. .Exhibit A, Page 2
`
`

`
`Case 3:15—cv—00189-PK Document 21
`
`Filed 03/23/15 Page 8 of 10
`
`(hi tfpmi ubtgiiiiiiig the i\’D.»‘\ approvals. PAR/\('3t')N agrees that A.l.'l'.:\lRl.3 shail be the cxcltisix-c
`itiziiittthcturcr (>t‘thc l’RC)l‘)i..3(L‘TS for l’:\RA('i(f)N during the term ufthc A('3Rl:Il%IMl'€:’\."'l".
`
`§_‘_(i)i\j l‘“l_D Eil§l_'l_'l Al .l:[:§//EON —Dj§(_".‘.l.,OS i. l R l:':_
`
`l’AR.:\('f5-(')N. and any of its directors, officers, employees. consultants, agents. servants and/or
`l.
`assigiis. ackn<)wledge. and agree that any./all CMC writings. documents, data and/or information
`disclosed pursuant to tlic ACil{Ef3IvliEIN’l“ are the proprietary and confidential
`infomuition of
`_t’\i.,T.»\iR.li{ (liercintiftcr the “Al."l"AlRl3 l'NI“ORMATl()N“)- and is provided for the limited
`ptt.t'p0Sc$ Mubtaining the NI.)/w\ approvals contemplated by this AGRF.F,Ml'~l. Vi‘. The Al..'l‘.-’~\lRl'j~‘.
`1Nl7(JR€\'lA'l'dl(f.)N am)‘ not be used l1>rany other purpose, nor disclosed to any third party without
`the written consent of z\l.'l".!\IRF,’s: principals.
`l".'\RAC.‘:(.“)N shall ensure that any of its niiiccrs.
`c‘lTtplt)}’L’C";‘S. c<.mstiliant5. agents. servants and/or assigns to whom disclosure of the Al..'l".»\lRl?‘.
`li\il"‘ORi\'l.‘\.l‘l0i\i
`is nt-:ccssat‘y are under written coiilidciitiality ubligzititms to Pz\R.-'\(‘.i():\i
`stifticient for it to comply with all the provisions of this Agrecnictit.
`
`is the proprietary and contirir:nti:il
`l’ARA(7fi()N ttirthcr acknmvlcdgers that such inforrnzitimi
`iitiiwirititititi of Al..'l"/\lR.lIZ, without r¢.gard to whether such ixithriiistticiri
`or t‘t‘t‘<’l_\~' be sulnjcctt to
`protection under any intemational. federal or state copyriglit, patent. trade secret or other laws. it
`being the specific intent‘ ofthe parties that the provisions of’ this Agreement are to be in addition
`to any pr<>t'ectii0n. right or remedy otherwise provided by law ur available in equity. P./~\.RA(..i()l\i
`tiirtlicrr zicknowlmlgcs that
`the disclosure oi‘ the Al..TAIRiEl
`lNI*'ORMA'l"l()N hereto dues not
`grant
`to
`l’AR.ACi(.)N any
`license,
`right
`in‘ ownersliip
`interest
`in
`such
`/\l..‘l‘A.lfR.l:{
`lNl~7(l)Rl\»1:’\'l'l(r)N. including but not limitcd to the right tu publish or otherwise ittztkc cmmnmtizil
`USL‘ tit" sticli inl'm'niati(m.
`
`I-"or ptii'pc>ses liereotl excluded front ",z\l.,'i‘AIRl}l lNF(f)RMA'l‘l()N“ is inforrnation Falliiig within
`any 0t"t‘ht-2 fallciwing catcgmics, provided P.~'\RAGON can clttarly and comincingly dcinonstratc
`that such infonnatimi meets the requirements as indicated lie,-rein:
`
`ini'm’m'.1tirm zilrcaciy known to or othcrwisc in the p()S$CS$i()l1 of i’ARA(3(“)N? prior to the
`ti)
`time the (llSCl(“)$ttt‘C of the Ai.TAIRlZ l?\il"()l{lv1A'!"l()i\.’;
`
`inl‘0rmatic.in publicly’ availablc or t)1li€'.‘l’\¥iSC in thc public domain Ihrotigh no fault ritinr
`(ii)
`action by l’AR/\(i(f)N;
`
`indcpcitdutttly discm'cr'cd after thc date licrcof by PARz\(.'i()i\5
`int'm‘in;-ttitin which is
`(iii)
`xxithnut the: aid. uppliczition or use oi‘. as applicable. the AI.T'AlRl}I lNl'~"(")R.MAT'lO?\i: and
`
`iiilmination I‘igl1I’l'itll}*’ obtained after the date liereof by l’AR.ACiON from any third part)-'
`(iv)
`which is lziwfiilly in pOSSCSSlOn of $tlCl1 inii‘>i'inatimi and xx-hich is provided by such third party
`without violating an)‘ contractual or lcgzil obligzition of such third part};
`to Al_.T/*\lR1:{ \-with
`respect to such iiiiorinution.
`
`J)
`
`/, ....\
`
`Exhibit A, Pageé
`
`‘
`
`_
`
`;
`
`*
`
`

`
`Case 3:15—cv—00189-PK Document 21
`
`Filed 03/23/15 Page 9 of 10
`
`i
`
`ii. The parties t"urthcr ac-k.nowlt:-.dgc and agree t.hztt arty:/all writings. documents, dotzt ztrtd.!ot'
`ittl‘c>t'nt."~tt.ion that reveals the ‘linttncial data and business information relating to (1 p23l'l}" are the
`propt'ietai'y and contidential
`information oi’ such party. and may not be disclosed to any third
`pttrl“)' witltottt the written consent of
`said patty.
`For purposes hereof. excluded from such
`proprietary and confidentiai
`int"ormation is ll’ilt)l'Itt31'l0n falling within any ol‘ the following
`CLtlC‘«l_.‘.0l'lCS.
`pr(>\’l(lC(l
`the discloscc can clearly and convincittgl_v dctnonstrutc that
`sttclt
`iiilortiizttititt meets the requirements as indicated hcrcin:
`
`inl’orrn21tiort already known to or otherwise in l.l1c‘: posscssioti of‘ at party prior to the time
`ti)
`the <lis;c.lostt.t‘c* ofsuclt inforn"tation;
`
`infomtatiort publicly available or otherwise in the public domain through no fault oi‘ or
`(ii)
`ztction ol'zt pat't'y.
`
`liN'lf
`
`thereof. without obtaining the prior
`this Agreement, nor any part
`Neither party shall assigtt
`€.\pr€-SS written consent of the other. This Agreentent shall be binding upon. and shall inure to
`the bcnclit oi". the parties hereto and their respective heirs. legal rcprcscnt'ritivc. successcsrs. and
`?.1S‘:ilL’.ll$i.
`
`.\$o action taken by 3 party in Ct')llllL‘Cli0rl with this /\grec:ntent,. including zany inxicstigatitnn by or
`on hchalt"ol’sttch party, shall be deeincd to constitute a waiver by such party o t‘ cotnpliancc with
`any rcpt'cscntation.
`\.vat':'z~1ttt.y.
`\.‘()\‘Cll‘<1ni. or agreement contained herein. or in any document
`dclixcrcci by the other }I3‘c1l'l')" in connection with the activities contctnplated by this Agtecttieitt.
`The w;~ti\'er b_'
`at party of at breach of Em)’ pro\-'ision of this Agrectttcttt. shall not operatt-2 or he
`con.~:t.rttcd as it xx-'ai\-'01‘ ol'ztn_\’ stthscqticttt hr ‘€lCll.
`
`a’\()'l‘l(.'
`
`.<\ll noticm. reqttcsts. demands and other coinntunications which are mqtiircd or may be given
`untilcr this .»‘\gre¢incnt shall he in writing and shall be deemed to have been duly git-‘en \\'llt;‘n
`rccc.i\=cd if‘ pcrsortally clclivcrcd; the dzty afier it is sent. ilisent by recognized expedited deliver)"
`_~;cr\-‘ice; and live days ztftcr it is sent
`ii‘ tnailed, first class mail. postage prepaid.
`in each case
`notice shall be sent to the 2t(‘ldl‘t3S$ set forth on the signature. page hcrcoi’. or to such other addmss
`as either pzirt}; shall ltave specified by notice in writing to the other part}.-'.
`
`
`
`This Agrcetnent shall be hinding upon and inure to the benefit ofthe SuCL‘C:'$S()l'.*5 in intt:x'c"5t ol'thc
`part.tt:S.
`
`
`
`

`
` _. .
`
`Case 3:15—cv—0O189-PK Document 21
`.
`,
`.
`.
`.._.., .. ,. _
`.
`.
`.
`\4
`.
`.
`, .....
`..
`..
`..
`.
`.
`.
`.. t.
`.
`.,
`.
`.
`
`1
`
`.
`
`.
`
`.
`
`Filed 03/23/15 Page 10 of 10
`._......... ..........-....-....._.‘.t.................w._.....M ,......... N.._........._....;_.__i...t................_N....,
`
`.
`
`.
`
`..,,
`
`The parties to this Agretrtttent agree that jurisdiction and vettuc ofany action brought pursuztnt to
`this Agreetttent, to enforce the term hereofor otherwise with respect to the relaticmships i.')€.‘i\.\‘Ct.‘ll
`the parties crcztted (tr extended pursuant lteretn, sh-all properly lie in the Ct>urt(s) of the. State til"
`New Yt>rk. or the (I‘ottrt(s) of the United States ltaving jurisdictimi over Sttffolk Cottnl)‘. Next
`Ym‘i<.
`
`.§.l:i.T.I¥Iii,l*§;:§z..E§l.i:1.IiLfxI.
`
`Wherever possible, each provision of this Agretztncnt shall be interpreted in such it tnzmncr as to
`bc valid of fuli force and ct‘t"¢ct. but ifany prO\-’iSiOt} cut’ this Agreement shall he pmhihited by or
`invalid under applicable law, such provision shall be ineffectixrc only to the cxtcitt of such
`prohibition or
`invalidity, without
`invalidating the remainder of such provisions of this;
`Agreement.
`
`j.€3.§iE§l§.i‘J..1\LL_._<75 L./t\_lv};’
`
`lite \'2tiidil‘}~. C()IlSII’ltCii0l1 and CI1ii(trCCm(‘Il‘t1 (iii and the remedies under. this ;\grecntet11 shall be
`\:20\'Cl‘llCL'i
`in ztccurdztttcc with the laws of the State of New York (except any choice oi‘ law
`prmxision o1'"Ncw York law shall not apply if the law of 21 state or jurisdiction other than ':\Et:w
`Ynrit tmulcl apply thereby).
`
`l?;Xi‘ECL,i'l"lON
`
`IN \J\"l'l‘E\t'f_§SS W}-1'1’-ZRl{:'(f)l?“. we agree. to the terms set out herein as ofthe date set ‘forth below.
`
`:‘\il’c1it‘t‘ i’lta.rnt:tcctttic2tl5. lnc.
`31 l
`\’~'est lane
`-’\kl“€l‘<Jgttc. New Yin" I 193
`
`
`
`l:)zttc:~é/[_/Q01 I
`
`Paragon l3i0Tcck, Inc.
`5 Cientcrpoiittc: Dtz. Suite 400
`l.,ak5:r ‘ *wego.(\‘)’t‘€'gott 97035
`v‘
`\~::.:.
`
`B)’; \ ().i,q,M_,.«\.*'/
`I";’i
`(',.;.»".~(—-{V-—~...————»»»»»--~
`(8 ignaturc)
`Patt'ici< W itham
`
`Date:
`
`‘T? 3vg‘_"_‘.{;’___w__fl__